FDA Divulges Cosmetics Enforcement Data, Notes Hair Loss As ‘Serious’ AE
This article was originally published in The Rose Sheet
Executive Summary
Momentum this year behind legislative proposals for cosmetics regulatory reform has prompted key Congress members to question FDA about the current oversight system. In a response to the Senate HELP Committee’s chairman, FDA provides a wealth of data on its enforcement activities and confirms hair loss as an adverse event it considers “serious,” if not one currently identified as such by MedWatch’s definition.